681 studies found for:    Herceptin
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
Condition: Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla];   Drug: Trastuzumab;   Drug: Docetaxel
2 Unknown  MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
Conditions: HER2 Amplified Breast Cancer;   Metastatic or Advanced Breast Cancer
Intervention: Drug: MM-111 and Herceptin
3 Completed CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
Condition: Carcinoma, Breast
Interventions: Drug: 0.04 mg/kg CpG 7909;   Drug: Herceptin®;   Drug: 0.08 mg/kg CpG 7909;   Drug: 0.12 mg/kg CpG 7909;   Drug: 0.16 mg/kg CpG 7909
4 Completed Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Condition: Carcinoma, Metastatic Breast
Interventions: Drug: CPG 7909;   Drug: Herceptin®
5 Active, not recruiting A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
Condition: Advanced Breast Cancer
Interventions: Drug: HKI-272;   Drug: Herceptin
6 Completed A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)
Condition: Healthy
Interventions: Biological: PF-05280014;   Biological: Herceptin
7 Recruiting A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2-Positive Metastatic Breast Cancer Patients
Condition: HER2-positive Metastatic Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Paclitaxel
8 Completed
Has Results
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Conditions: Breast Cancer;   Neoplasm Metastasis
Interventions: Drug: Trastuzumab;   Drug: RAD001
9 Completed
Has Results
Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Herceptin;   Drug: Navelbine;   Drug: Taxotere;   Drug: Carboplatin
10 Recruiting Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
Condition: Esophageal Carcinoma
Intervention: Drug: Pertuzumab, trastuzumab
11 Not yet recruiting Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Conditions: Bone Metastases;   HER2-positive Breast Cancer;   Liver Metastases;   Lung Metastases;   Recurrent Breast Cancer;   Soft Tissue Metastases;   Stage IV Breast Cancer
Interventions: Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography;   Biological: trastuzumab;   Radiation: copper Cu 64-DOTA-trastuzumab;   Biological: ado-trastuzumab emtansine;   Other: laboratory biomarker analysis
12 Terminated Neoadjuvant Herceptin in Patients With Breast Cancer
Condition: BREAST CANCER
Intervention: Drug: Herceptin
13 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
Condition: Metastatic Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg;   Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg;   Drug: Pertuzumab 420 mg
14 Completed Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Drug: carboplatin;   Drug: docetaxel;   Biological: trastuxumab;   Drug: Docetaxel
15 Active, not recruiting Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Trastuzumab
16 Completed Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Herceptin;   Drug: Taxol;   Drug: Fluorouracil;   Drug: Cytoxan;   Drug: Epirubicin
17 Active, not recruiting Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
Condition: Advanced Cancers
Interventions: Drug: Pazopanib;   Drug: Lapatinib;   Drug: Trastuzumab (Herceptin®)
18 Active, not recruiting Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Lapatinib;   Drug: Herceptin
19 Terminated Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
Condition: Metastatic Breast Cancer
Interventions: Drug: G-CSF;   Drug: trastuzumab;   Drug: vinorelbine;   Drug: saline
20 Recruiting Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Condition: Breast Cancer
Interventions: Drug: Herceptin;   Drug: NeuVax vaccine;   Drug: GM-CSF

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years